Clene to Present at Upcoming October Conferences
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases like ALS and MS, has announced its participation in two upcoming investor conferences in October 2024.
The company will attend the 2024 Maxim Healthcare Virtual Summit from October 15-17, with a fireside presentation scheduled for October 15 at 2:30 p.m. E.T. Clene will also participate in The ThinkEquity Conference 2024 on October 30 in New York City, presenting at 3:30 p.m. E.T.
Both events will feature presentations and one-on-one meetings. For the Maxim Healthcare Virtual Summit, interested parties can sign up to become M-Vest members. The ThinkEquity Conference presentation will be accessible via webcast.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CLNN gained 14.04%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in October.
2024 Maxim Healthcare Virtual Summit
Date: October 15-17, 2024
Location: Virtual
Presentation: October 15, 2024, at 2:30 p.m. E.T.
Format: Fireside Presentation and 1x1 meetings
Attendance: Sign up to become an M-Vest member
The ThinkEquity Conference 2024
Dates: October 30, 2024
Location: New York, New York, Mandarin Oriental Hotel
Presentation: October 30, 2024, at 3:30 p.m. E.T.
Format: Presentation and 1x1 meetings
Webcast Link: https://wsw.com/webcast/tep25/clnn/1673136
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Contacts:
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856 |
FAQ
What investor conferences will Clene Inc. (CLNN) attend in October 2024?
When is Clene's (CLNN) presentation at the 2024 Maxim Healthcare Virtual Summit?
Where can I watch Clene's (CLNN) presentation at The ThinkEquity Conference 2024?
What neurological diseases does Clene Inc. (CLNN) focus on treating?
